RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance

U.S. Markets open in 3 hrs 28 mins

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
27.67+0.47 (+1.73%)
At close: 3:59 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close27.20
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume1,114,593
Market Cap197.57B
PE Ratio (TTM)21.36
Earnings DateN/A
Dividend & Yield1.02 (3.74%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Bloomberg4 hours ago

    J&J Woos Billionaire Doctors Who Don’t Need Cash in Actelion Bid

    Jean-Paul and Martine Clozel represent the dream of just about every pharmaceutical researcher. After the multinational that employed them declined to pursue a compound they discovered, the Clozels founded ...

  • Amgen/Allergan File for EU Approval of Avastin Biosimilar
    Zacks20 hours ago

    Amgen/Allergan File for EU Approval of Avastin Biosimilar

    Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

  • Reuters21 hours ago

    Study raises questions over benefit of Roche's Gazyva cancer drug

    Roche's Gazyva cancer drug did not show a significant overall survival benefit and raised greater safety concerns than its predecessor Rituxan, a study showed, raising doubts over the Swiss pharmaceuticals group's bid to replace a key blockbuster. Gazyva is used with the chemotherapy drug bendamustine to treat follicular lymphoma (FL) and Roche is counting on it to help mitigate the impact of biosimilars on Rituxan, whose patents expired this year.. Roche failed to find a follow-up drug to its Avastin blockbuster this year and faces competition from rivals including Novartis whose Sandoz generics unit is hot on Rituxan's heels.